| 1 |
Bukhari I, Khan MR, Li F, Swiatczak B, Thorne RF, Zheng P, Mi Y. Clinical implications of lncRNA LINC-PINT in cancer. Front Mol Biosci 2023;10. [DOI: 10.3389/fmolb.2023.1097694] [Reference Citation Analysis]
|
| 2 |
Meng L, Wang Y, Tu Q, Zhu Y, Dai X, Yang J. Circular RNA circ_0000741/miR-379-5p/TRIM14 signaling axis promotes HDAC inhibitor (SAHA) tolerance in glioblastoma. Metab Brain Dis 2023. [PMID: 36905560 DOI: 10.1007/s11011-023-01184-9] [Reference Citation Analysis]
|
| 3 |
Guo X, Gao C, Yang DH, Li S. Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance. Drug Resist Updat 2023;67:100937. [PMID: 36753923 DOI: 10.1016/j.drup.2023.100937] [Reference Citation Analysis]
|
| 4 |
Kuang S, Wang J, Wei Z, Zhai F, Liang S. The regulatory function of lncRNA and constructed network in epilepsy. Neurol Sci 2023. [PMID: 36781564 DOI: 10.1007/s10072-023-06648-5] [Reference Citation Analysis]
|
| 5 |
Zhao Y, Tang C, Huang J, Zhang H, Shi J, Xu S, Ma L, Peng C, Liu Q, Xiong Y. Screening Multidrug Resistance Reversal Agents in Traditional Chinese Medicines by Efflux Kinetics of D-Luciferin in MCF-7/DOX(Fluc) Cells. ACS Omega 2023;8:4853-61. [PMID: 36777569 DOI: 10.1021/acsomega.2c07096] [Reference Citation Analysis]
|
| 6 |
Pan Y, Zhang Q, Zhang H, Kong F. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Funct Integr Genomics 2023;23:38. [PMID: 36640225 DOI: 10.1007/s10142-023-00963-y] [Reference Citation Analysis]
|
| 7 |
Li J, Zhu L, Kwok HF. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. Drug Resist Updat 2023;66:100904. [PMID: 36462375 DOI: 10.1016/j.drup.2022.100904] [Reference Citation Analysis]
|
| 8 |
Zhou H, Yuan Y, Wang Z, Ren Z, Hu M, Lu J, Gao H, Pan C, Zhao W, Zhu B. Co-delivery of doxorubicin and quercetin by Janus Hollow Silica Nanomotors for overcoming multidrug resistance in breast MCF-7/Adr cells. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2022. [DOI: 10.1016/j.colsurfa.2022.130654] [Reference Citation Analysis]
|
| 9 |
Zhang X, Luo M, Zhang J, Guo B, Singh S, Lin X, Xiong H, Ju S, Wang L, Zhou Y, Zhou J. The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. Front Genet 2022;13:1005522. [DOI: 10.3389/fgene.2022.1005522] [Reference Citation Analysis]
|
| 10 |
Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates 2022;65:100866. [DOI: 10.1016/j.drup.2022.100866] [Reference Citation Analysis]
|
